These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33081540)

  • 21. Developments of CRBN-based PROTACs as potential therapeutic agents.
    Wang C; Zhang Y; Wu Y; Xing D
    Eur J Med Chem; 2021 Dec; 225():113749. PubMed ID: 34411892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PROTACs: Novel approach for cancer breakdown by breaking proteins.
    Memon H; Patel BM
    Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs.
    Bondeson DP; Smith BE; Buhimschi AD
    Methods Mol Biol; 2021; 2365():135-150. PubMed ID: 34432242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Present and Future of Novel Protein Degradation Technology.
    Xia L; Liu W; Song Y; Zhu H; Duan Y
    Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
    Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
    Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
    Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
    Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
    Si R; Hai P; Zheng Y; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
    Bioorg Med Chem Lett; 2023 May; 87():129275. PubMed ID: 37030566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
    Mares A; Miah AH; Smith IED; Rackham M; Thawani AR; Cryan J; Haile PA; Votta BJ; Beal AM; Capriotti C; Reilly MA; Fisher DT; Zinn N; Bantscheff M; MacDonald TT; Vossenkamper A; Dace P; Churcher I; Benowitz AB; Watt G; Denyer J; Scott-Stevens P; Harling JD
    Commun Biol; 2020 Mar; 3(1):140. PubMed ID: 32198438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROTACs to address the challenges facing small molecule inhibitors.
    Martín-Acosta P; Xiao X
    Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
    Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation.
    Gross PH; Sheets KJ; Warren NA; Ghosh S; Varghese RE; Wass KWass KE; Kadimisetty K
    Biochem Biophys Res Commun; 2022 Nov; 628():68-75. PubMed ID: 36084553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted protein degradation: elements of PROTAC design.
    Paiva SL; Crews CM
    Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.